{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T17:04:47Z","timestamp":1747155887905,"version":"3.40.5"},"reference-count":96,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","annalsofvascularsurgery.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Vascular Surgery"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.avsg.2024.01.027","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T16:25:53Z","timestamp":1712247953000},"page":"170-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Medical Optimization of Patients with Symptomatic Peripheral Arterial Disease"],"prefix":"10.1016","volume":"107","author":[{"given":"Abdelrhman","family":"Abumoawad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A.","family":"Okazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leili","family":"Behrooz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5076-7416","authenticated-orcid":false,"given":"Robert T.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.avsg.2024.01.027_bib1","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1161\/CIR.0000000000001005","article-title":"Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement from the American Heart Association","volume":"144","author":"Criqui","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib2","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral arterial disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib3","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.jvs.2015.07.065","article-title":"The natural history of untreated severe or critical limb ischemia","volume":"62","author":"Abu Dabrh","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib4","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/ATVBAHA.120.314595","article-title":"Epidemiology and risk of amputation in patients with diabetes mellitus and peripheral artery disease","volume":"40","author":"Barnes","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.avsg.2024.01.027_bib5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.avsg.2021.04.037","article-title":"Peripheral artery disease leading to major amputation: trends in revascularization and mortality over 18 years","volume":"78","author":"Abry","year":"2022","journal-title":"Ann Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib6","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCULATIONAHA.117.027625","article-title":"Thirty-day readmissions after endovascular or surgical therapy for critical limb ischemia: analysis of the 2013 to 2014 nationwide readmissions databases","volume":"136","author":"Kolte","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib7","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1161\/CIRCRESAHA.121.318243","article-title":"Racial and ethnic disparities in peripheral artery disease","volume":"128","author":"Hackler","year":"2021","journal-title":"Circ Res"},{"key":"10.1016\/j.avsg.2024.01.027_bib8","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.amepre.2006.12.010","article-title":"Ethnic-specific prevalence of peripheral arterial disease in the United States","volume":"32","author":"Allison","year":"2007","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1053\/j.semvascsurg.2022.05.003","article-title":"Disparities in peripheral artery disease care: a review and call for action","volume":"35","author":"Demsas","year":"2022","journal-title":"Semin Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib10","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1532-5415.2003.51061.x","article-title":"Sex differences in peripheral arterial disease: leg symptoms and physical functioning","volume":"51","author":"McDermott","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.avsg.2024.01.027_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3122\/jabfm.19.2.132","article-title":"Gender and peripheral arterial disease","volume":"19","author":"Collins","year":"2006","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib12","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1161\/CIR.0000000000000623","article-title":"Optimal exercise programs for patients with peripheral artery disease: a scientific statement from the American Heart Association","volume":"139","author":"Treat-Jacobson","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib13","first-page":"e686","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib14","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.avsg.2024.01.027_bib15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/dom.14700","article-title":"Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease","volume":"24","author":"Verma","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.avsg.2024.01.027_bib17","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012806","article-title":"Stimulation of collateral vessel growth by inhibition of galectin 2 in mice using a single-domain llama-derived antibody","volume":"8","author":"Hollander","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.avsg.2024.01.027_bib18","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.atherosclerosis.2020.05.012","article-title":"The NO-donor MPC-1011 stimulates angiogenesis and arteriogenesis and improves hindlimb ischemia via a cGMP-dependent pathway involving VEGF and SDF-1alpha","volume":"304","author":"Gomes de Almeida Schirmer","year":"2020","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.avsg.2024.01.027_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173233","article-title":"N-acetylcysteine differentially regulates the populations of bone marrow and circulating endothelial progenitor cells in mice with limb ischemia","volume":"881","author":"Cui","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.avsg.2024.01.027_bib20","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.3390\/ijms21082821","article-title":"IL10 alters peri-collateral macrophage polarization and hind-limb reperfusion in mice after femoral artery ligation","volume":"21","author":"Gotze","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.avsg.2024.01.027_bib21","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Antithrombotic Trialists","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2024.01.027_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2024.01.027_bib23","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/bmj.308.6921.81","article-title":"Collaborative overview of randomised trials of antiplatelet therapy--I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration","volume":"308","year":"1994","journal-title":"BMJ"},{"key":"10.1016\/j.avsg.2024.01.027_bib24","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1001\/jama.2009.623","article-title":"Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials","volume":"301","author":"Berger","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0135692","article-title":"Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis","volume":"10","author":"Katsanos","year":"2015","journal-title":"PLoS One"},{"issue":"3 Suppl","key":"10.1016\/j.avsg.2024.01.027_bib26","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/j.jvs.2014.12.009","article-title":"Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication","volume":"61","author":"Conte","year":"2015","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee","volume":"348","author":"Committee","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2024.01.027_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/1358863X18775594","article-title":"Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: insights from the EUCLID trial","volume":"23","author":"Berger","year":"2018","journal-title":"Vasc Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib30","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jacc.2021.09.005","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: executive summary: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Writing Committee","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib31","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib32","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/eurheartj\/ehn534","article-title":"Patients with peripheral arterial disease in the CHARISMA trial","volume":"30","author":"Cacoub","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.avsg.2024.01.027_bib33","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib34","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1583\/13-4275MR.1","article-title":"Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease","volume":"20","author":"Strobl","year":"2013","journal-title":"J Endovasc Ther"},{"key":"10.1016\/j.avsg.2024.01.027_bib36","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2012.08.989","article-title":"A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial","volume":"60","author":"Scheinert","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.119.008791","article-title":"Discharge prescription patterns for antiplatelet therapy following lower extremity peripheral vascular intervention","volume":"13","author":"Singh","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2024.01.027_bib38","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jcin.2019.08.006","article-title":"Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease","volume":"12","author":"Cho","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2024.01.027_bib39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.17925\/HI.2021.15.1.14","article-title":"Medical therapy for secondary prevention of atherothrombotic events in peripheral artery disease","volume":"15","author":"Morrison","year":"2021","journal-title":"Heart Int"},{"key":"10.1016\/j.avsg.2024.01.027_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jcin.2021.01.035","article-title":"The role for combined antithrombotic therapy with platelet and coagulation inhibition after lower extremity revascularization","volume":"14","author":"Weissler","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2024.01.027_bib41","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.120.009584","article-title":"Contemporary review of antithrombotic therapy in peripheral artery disease","volume":"13","author":"Hess","year":"2020","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2024.01.027_bib42","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib43","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib44","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2024.01.027_bib45","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S0140-6736(99)07199-8","article-title":"Efficacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2024.01.027_bib46","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib47","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1016\/j.jcin.2016.07.034","article-title":"Peripheral revascularization in patients with peripheral artery disease with vorapaxar: insights from the TRA 2 degrees P-TIMI 50 trial","volume":"9","author":"Bonaca","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.avsg.2024.01.027_bib48","first-page":"e13","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.avsg.2024.01.027_bib49","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1055\/a-0588-7317","volume":"143","author":"Sansone","year":"2018","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.avsg.2024.01.027_bib50","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib51","article-title":"Treatment of hypertension in peripheral arterial disease","volume":"4","author":"Lane","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.avsg.2024.01.027_bib52","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jvs.2020.02.041","article-title":"Improved survival with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic limb-threatening ischemia","volume":"72","author":"Khan","year":"2020","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib53","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Investigators","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib54","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.jvs.2006.12.054","article-title":"Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions","volume":"45","year":"2007","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib55","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.117.032361","article-title":"Association of statin dose with amputation and survival in patients with peripheral artery disease","volume":"137","author":"Arya","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib57","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00003088-200544050-00002","article-title":"Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions","volume":"44","author":"Kosoglou","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.avsg.2024.01.027_bib58","doi-asserted-by":"crossref","first-page":"212534","DOI":"10.7573\/dic.212534","article-title":"Adding ezetimibe to statin therapy: latest evidence and clinical implications","volume":"7","author":"Vavlukis","year":"2018","journal-title":"Drugs Context"},{"key":"10.1016\/j.avsg.2024.01.027_bib59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"West","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.avsg.2024.01.027_bib60","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11883-016-0611-4","article-title":"Bempedoic acid (ETC-1002): an investigational inhibitor of ATP citrate lyase","volume":"18","author":"Bilen","year":"2016","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.avsg.2024.01.027_bib61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2165\/00003495-198734010-00003","article-title":"Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy","volume":"34","author":"Ward","year":"1987","journal-title":"Drugs"},{"key":"10.1016\/j.avsg.2024.01.027_bib62","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1097\/00005344-199311000-00007","article-title":"Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers","volume":"22","author":"Demolis","year":"1993","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.avsg.2024.01.027_bib63","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1139\/y96-088","article-title":"Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative: a study in healthy male subjects","volume":"74","author":"Nony","year":"1996","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.avsg.2024.01.027_bib64","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9343(00)00569-6","article-title":"A comparison of cilostazol and pentoxifylline for treating intermittent claudication","volume":"109","author":"Dawson","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib65","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(66)92191-X","article-title":"Effect of daily muscular exercise in patients with intermittent claudication","volume":"2","author":"Larsen","year":"1966","journal-title":"Lancet"},{"key":"10.1016\/j.avsg.2024.01.027_bib66","first-page":"H679","article-title":"Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle","volume":"276","author":"Gustafsson","year":"1999","journal-title":"Am J Physiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib67","first-page":"D75","article-title":"Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology","volume":"6","author":"Gustafsson","year":"2001","journal-title":"Front Biosci"},{"key":"10.1016\/j.avsg.2024.01.027_bib68","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/S0735-1097(96)00393-2","article-title":"Cardiovascular effects of exercise: role of endothelial shear stress","volume":"28","author":"Niebauer","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib69","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1152\/jappl.1992.73.1.346","article-title":"Skeletal muscle carnitine metabolism in patients with unilateral peripheral arterial disease","volume":"73","author":"Hiatt","year":"1992","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.avsg.2024.01.027_bib70","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1152\/jappl.1996.81.2.780","article-title":"Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease","volume":"81","author":"Hiatt","year":"1996","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.avsg.2024.01.027_bib71","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2014.12.043","article-title":"Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study","volume":"65","author":"Murphy","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000990.pub2","article-title":"Exercise for intermittent claudication","author":"Watson","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.avsg.2024.01.027_bib73","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.34590","article-title":"Home-based walking exercise and supervised treadmill exercise in patients with peripheral artery disease: an individual participant data meta-analysis","volume":"6","author":"Thangada","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.avsg.2024.01.027_bib74","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.2008.962","article-title":"Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial","volume":"301","author":"McDermott","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib75","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1001\/jama.2017.17437","article-title":"Effect of granulocyte-macrophage colony-stimulating factor with or without supervised exercise on walking performance in patients with peripheral artery disease: the PROPEL randomized clinical trial","volume":"318","author":"McDermott","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib76","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1001\/jama.2022.16797","article-title":"Effect of telmisartan on walking performance in patients with lower extremity peripheral artery disease: the TELEX randomized clinical trial","volume":"328","author":"McDermott","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2013.7231","article-title":"Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial","volume":"310","author":"McDermott","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib78","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2021.2536","article-title":"Effect of low-intensity vs high-intensity home-based walking exercise on walk distance in patients with peripheral artery disease: the LITE randomized clinical trial","volume":"325","author":"McDermott","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib79","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1358863X211060388","article-title":"Safety of home-based exercise for people with intermittent claudication: a systematic review","volume":"27","author":"Waddell","year":"2022","journal-title":"Vasc Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib80","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib81","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib82","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study","volume":"42","author":"Paul","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.avsg.2024.01.027_bib83","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1007\/s00125-019-4839-8","article-title":"Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program","volume":"62","author":"Matthews","year":"2019","journal-title":"Diabetologia"},{"key":"10.1016\/j.avsg.2024.01.027_bib84","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib85","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000520903","article-title":"Effects of sodium-glucose cotransporter 2 on amputation events: a systematic review and meta-analysis of randomized-controlled trials","volume":"107","author":"See","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.avsg.2024.01.027_bib86","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib87","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib88","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: a subanalysis of EMPA-REG OUTCOME","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib89","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1161\/01.CIR.82.6.1925","article-title":"Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study","volume":"82","author":"Smith","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.avsg.2024.01.027_bib90","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1001\/jama.2019.10298","article-title":"Association of smoking cessation with subsequent risk of cardiovascular disease","volume":"322","author":"Duncan","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.avsg.2024.01.027_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2023.1154708","article-title":"A modern day perspective on smoking in peripheral artery disease","volume":"10","author":"Behrooz","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib92","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1002\/bjs.1800691309","article-title":"The measured effect of stopping smoking on intermittent claudication","volume":"69 Suppl","author":"Quick","year":"1982","journal-title":"Br J Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jamacardio.2021.3979","article-title":"Association of smoking with postprocedural complications following open and endovascular interventions for intermittent claudication","volume":"7","author":"Reitz","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.avsg.2024.01.027_bib94","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jvs.2005.03.024","article-title":"Smoking and the patency of lower extremity bypass grafts: a meta-analysis","volume":"42","author":"Willigendael","year":"2005","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.avsg.2024.01.027_bib95","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1001\/jamainternmed.2018.0397","article-title":"Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial","volume":"178","author":"Benowitz","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.avsg.2024.01.027_bib96","first-page":"e726","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"135","author":"Gerhard-Herman","year":"2017","journal-title":"Circulation"}],"container-title":["Annals of Vascular Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624001602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890509624001602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T18:15:31Z","timestamp":1731694531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890509624001602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":96,"alternative-id":["S0890509624001602"],"URL":"https:\/\/doi.org\/10.1016\/j.avsg.2024.01.027","relation":{},"ISSN":["0890-5096"],"issn-type":[{"type":"print","value":"0890-5096"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Optimization of Patients with Symptomatic Peripheral Arterial Disease","name":"articletitle","label":"Article Title"},{"value":"Annals of Vascular Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.avsg.2024.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}